Favorable Media Coverage Somewhat Unlikely to Affect Catabasis Pharmaceuticals (CATB) Share Price

News stories about Catabasis Pharmaceuticals (NASDAQ:CATB) have been trending positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.4599425097191 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) traded up $0.21 during midday trading on Friday, hitting $1.60. 5,523,606 shares of the stock traded hands, compared to its average volume of 1,752,300. The company has a market cap of $36.93, a price-to-earnings ratio of -1.06 and a beta of 1.20. Catabasis Pharmaceuticals has a one year low of $1.09 and a one year high of $3.78.

A number of equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Wedbush reissued an “outperform” rating and set a $4.00 price objective (down previously from $5.00) on shares of Catabasis Pharmaceuticals in a report on Wednesday. Finally, Citigroup raised shares of Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Monday, November 20th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $4.82.

COPYRIGHT VIOLATION NOTICE: “Favorable Media Coverage Somewhat Unlikely to Affect Catabasis Pharmaceuticals (CATB) Share Price” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2018/02/18/favorable-media-coverage-somewhat-unlikely-to-affect-catabasis-pharmaceuticals-catb-share-price.html.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Insider Buying and Selling by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit